Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.38 USD | +2.41% | +0.31% | -54.23% |
Financials (USD)
Sales 2024 * | 15.25M | Sales 2025 * | 11.36M | Capitalization | 523M |
---|---|---|---|---|---|
Net income 2024 * | -224M | Net income 2025 * | -260M | EV / Sales 2024 * | 4.22 x |
Net cash position 2024 * | 459M | Net cash position 2025 * | 228M | EV / Sales 2025 * | 26 x |
P/E ratio 2024 * |
-2.33
x | P/E ratio 2025 * |
-2.19
x | Employees | 255 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.7% |
Latest transcript on Verve Therapeutics, Inc.
1 day | +2.41% | ||
1 week | +4.93% | ||
Current month | +6.16% | ||
1 month | -12.72% | ||
3 months | -51.96% | ||
6 months | -44.47% | ||
Current year | -54.23% |
Managers | Title | Age | Since |
---|---|---|---|
Sekar Kathiresan
FOU | Founder | 52 | 17-12-31 |
Allison Dorval
DFI | Director of Finance/CFO | 48 | 21-11-28 |
Andrew Ashe
PSD | President | 57 | 18-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Burt Adelman
FOU | Founder | 71 | 17-12-31 |
Lonnel Coats
BRD | Director/Board Member | 58 | 22-08-07 |
Michael MacLean
BRD | Director/Board Member | 58 | 21-04-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.13% | 2 M€ | -25.75% | ||
3.54% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 6.38 | +2.41% | 2,139,757 |
24-05-15 | 6.23 | 0.00% | 1,254,733 |
24-05-14 | 6.23 | +0.16% | 1,494,031 |
24-05-13 | 6.22 | +3.49% | 1,723,340 |
24-05-10 | 6.01 | -5.50% | 1,604,714 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-54.23% | 523M | |
+33.37% | 49.46B | |
+1.55% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.57% | 26.61B | |
-21.00% | 18.64B | |
+7.36% | 13.16B | |
+28.30% | 12.55B | |
+23.80% | 12.1B |
- Stock Market
- Equities
- VERV Stock